[{"id":"91463b97-ebd1-4b46-aa50-28330829d950","acronym":"","url":"https://clinicaltrials.gov/study/NCT05577182","created_at":"2022-10-13T17:58:01.319Z","updated_at":"2024-07-02T16:34:26.137Z","phase":"Phase 1","brief_title":"Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies","source_id_and_acronym":"NCT05577182","lead_sponsor":"Incyte Corporation","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INCA32459"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 04/10/2026","primary_completion_date":" 04/10/2026","study_txt":" Completion: 04/10/2026","study_completion_date":" 04/10/2026","last_update_posted":"2024-06-14"}]